BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia
Charles Herbaux(Centre Hospitalier Universitaire de Lille), Matthew S. Davids(Dana-Farber Cancer Institute), Christoph Kornauth(Munich Leukemia Laboratory (Germany)), Stéphanie Poulain(Centre National de la Recherche Scientifique), Loïc Ysebaert(Institut universitaire du cancer de Toulouse Oncopole), Kamel Laribi(Centre Hospitalier du Mans), Liam Hackett(Dana-Farber Cancer Institute), Cécile Tomowiak(Inserm), Adrien Daniel(Centre Hospitalier Universitaire de Lille), Eric Van Den Neste(Cliniques Universitaires Saint-Luc), Philipp B. Staber(Vienna General Hospital), Cécile Leyronnas, François Lemonnier(Université Paris-Est Créteil), Mary C. Collins(Dana-Farber Cancer Institute), Franck Morschhauser(Hôpital Claude Huriez), Olivier Tournilhac, Stephen Jun Fei Chong(Harvard University), Loïc Renaud(Assistance Publique – Hôpitaux de Paris), Cédric Rossi(Stanford University), Fatiha Merabet(Hôpital André Mignot), Damien Roos‐Weil(Sorbonne Université), Jean Valère Malfuson(Hôpital d'instruction des Armées Percy), Mourad Tiab(Roche (France)), Rebecca Valentin(Dana-Farber Cancer Institute), Samuel Y. Ng(National Cancer Institute), Jehan Dupuis(Inserm)
Cited by 37
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595